The management of dyspnoea in chronic heart failure

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 2, 2010, Pages 63-68

  Johnson, Miriam J ^a   Oxberry, Stephen G ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Yorkshire Palliative Medicine Training Scheme   (United Kingdom)

Author keywords

Chronic heart failure; Dyspnoea; Management; Palliative care; Pharmacological interventions

Indexed keywords

BRONCHODILATING AGENT; DIURETIC AGENT; MORPHINE; NARCOTIC AGENT; VASODILATOR AGENT;

ALTERNATIVE MEDICINE; ARTICLE; DRUG CONTRAINDICATION; DYSPNEA; HEART FAILURE; HUMAN; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY;

BRONCHODILATOR AGENTS; COMBINED MODALITY THERAPY; DIURETICS; DYSPNEA; EXERCISE THERAPY; HEART FAILURE; HUMANS; MIND-BODY THERAPIES; MORPHINE; NARCOTICS; VASODILATOR AGENTS;

EID: 77953834074     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833929aa     Document Type: Article

References (41)

1. Oxberry SG, Johnson MJ. Review of the evidence for the management of dyspnoea in people with chronic heart failure. Curr Opin Support Palliat Care 2008; 2:84-88.
2. Pang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29:816-824.
3. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101:399-410.
4. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007; 21:177-191.
5. Dorman S, Jolley C, Abernethy A, et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009; 23:213-227.
6. Ekman I, Cleland JG, Swedberg K, et al. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail 2005; 11:288-292.
7. Johnson MJ, Oxberry SG, Cleland JG, Clark AL. Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardised approach. A systematic review. Eur J Heart Fail 2010; 12:137-147.
8. Rees K, Taylor RRS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation for heart failure (Review). Cochrane Database of Systematic Reviews 2009:CD003331.
9. Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1451-1459.
10. Pozehl B, Duncan K, Hertzog M. The effects of exercise training on fatigue and dyspnea in heart failure. Eur J Cardiovasc Nurs 2008; 7:127-132.
11. Sullivan MJ, Wood L, Terry J, et al. The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. Am Heart J 2009; 157:84-90.
12. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007; 30:861-881.
13. Slordal L, Spigset O. Heart failure induced by noncardiac drugs. Drug Saf 2006; 29:567-586.
14. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157:545-559.
15. Zhang H, Liu C, Ji Z, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J 2008; 49: 587-595.
16. Clark AL, McDonagh T. The origin of symptoms in chronic heart failure. Heart 1997; 78:429-430.
17. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007; 14:2181-2191.
18. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-2144.
19. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure (Review). Cochrane Database of Systematic Reviews 2006: CD003838.
20. Singer AJ, Emerman C, Char DM, et al. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med 2008; 51:25-34.
21. Boni E, Bezzi M, Carminati L, et al. Expiratory flow limitation is associated with orthopnea and reversed by vasodilators and diuretics in left heart failure. Chest 2005; 128:1050-1057.
22. Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother 2009; 10:311-322.
23. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14:631-640.
24. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50:1551-1560.
25. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287:1531-1540.
26. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005; 23:327-331.
27. Peacock WF. Initial results from the PROACTION study. J Emerg Med 2006; 31:435-436.
28. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296:2217-2226.
29. Miller AH, Nazeer S, Pepe P, et al. Acutely decompensated heart failure in a country emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment. Ann Emerg Med 2008; 51:571-578.
30. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebocontrolled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373:1429-1439.
31. Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 2008; 72:1777-1786.
32. Newton PJ, Davidson PM, MacDonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008; 36:424-441.
33. Newton PJ, Davidson PM, Krum H, Ollerton R, MacDonald P. Acute hemodynamic effects of nebulised furosemide in stable heart failure. J Card Fail 2009. [Abstract]
34. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008; 25:205-209.
35. Chua TP, Harrington D, Ponikowski P, et al. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997; 29:147-152. (Pubitemid 27028732)
36. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 2009; 33:771-777.
37. Pang PS, Tavares M, Collins SP, et al. Design and rationale of the URGENT dyspnea study: an international, multicenter, prospective study. Am J Ther 2008; 15:299-303.
38. Papp LA, Weiss JR, Greenberg HE, et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. Am J Psychiatry 1995; 152:1531.
39. Perna G, Cogo R, Bellodi L. Selective serotonin re-uptake inhibitors beyond psychiatry: are they useful in the treatment of severe, chronic, obstructive pulmonary disease? Depress Anxiety 2004; 20:203-204.
40. Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998; 39:24-29.
41. Simon ST, Bausewein C, Booth S, Harding R, Higginson I. Benzodiazepines for the relief of breathlessness in malignant and advanced nonmalignant diseases in adults (Protocol). Cochrane Database of Systematic Reviews 2008:CD007354.